Novo Nordisk’s ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025. read more ​Â
ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over enzalutamide alone, shifting focus to other priorities. read more ​Â
The electric truck manufacturer Nikola Corp. has yet to return several of the recalled battery electric trucks, causing delays and financial struggles. read more ​Â
Apple CEO Tim Cook expressed cautious optimism about Apple’s stable performance in China, highlighting record-high active devices and strong sales, while declining to speculate on the impact of China’s economic stimulus. read more ​Â
This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.
